Literature DB >> 11193145

The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy.

M G Spillantini1, M Goedert.   

Abstract

Parkinson's disease is the second most common neurodegenerative disease, after Alzheimer's disease. Neuropathologically, it is characterized by the degeneration of populations of nerve cells that develop filamentous inclusions in the form of Lewy bodies and Lewy neurites. Recent work has shown that the filamentous inclusions of Parkinson's disease are made of the protein alpha-synuclein and that rare, familial forms of Parkinson's disease are caused by missense mutations in the alpha-synuclein gene. Besides Parkinson's disease, the filamentous inclusions of two additional neurodegenerative diseases, namely, dementia with Lewy bodies and multiple system atrophy, have also been found to be made of alpha-synuclein. Recombinant alpha-synuclein has been shown to assemble into filaments with similar morphologies to those found in the human diseases and with a cross-beta fiber diffraction pattern. The new work has established the alpha-synucleinopathies as a major class of neurodegenerative disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11193145     DOI: 10.1111/j.1749-6632.2000.tb06900.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  161 in total

1.  Formation of cholesterol ozonolysis products in vitro and in vivo through a myeloperoxidase-dependent pathway.

Authors:  Susumu Tomono; Noriyuki Miyoshi; Hidemi Shiokawa; Tomoe Iwabuchi; Yasuaki Aratani; Tatsuya Higashi; Haruo Nukaya; Hiroshi Ohshima
Journal:  J Lipid Res       Date:  2010-10-04       Impact factor: 5.922

2.  Biochemical and morphological consequences of human α-synuclein expression in a mouse α-synuclein null background.

Authors:  Kavita Prasad; Elizabeth Tarasewicz; Pamela A Ohman Strickland; Michael O'Neill; Stephen N Mitchell; Kalpana Merchant; Samnang Tep; Kathryn Hilton; Akash Datwani; Manuel Buttini; Sarah Mueller-Steiner; Eric K Richfield
Journal:  Eur J Neurosci       Date:  2011-01-28       Impact factor: 3.386

Review 3.  Drug targets from genetics: α-synuclein.

Authors:  Karin M Danzer; Pamela J McLean
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

Review 4.  [Postmortal diagnosis of Parkinson's disease].

Authors:  D Sandmann-Keil; H Braak
Journal:  Pathologe       Date:  2005-05       Impact factor: 1.011

5.  Photo-activity induced by amyloidogenesis.

Authors:  Olga Tcherkasskaya
Journal:  Protein Sci       Date:  2007-02-27       Impact factor: 6.725

Review 6.  Amyloidogenesis of natively unfolded proteins.

Authors:  Vladimir N Uversky
Journal:  Curr Alzheimer Res       Date:  2008-06       Impact factor: 3.498

Review 7.  Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Pharmacol Ther       Date:  2013-02-04       Impact factor: 12.310

8.  Behavioral and histopathological consequences of paraquat intoxication in mice: effects of alpha-synuclein over-expression.

Authors:  P O Fernagut; C B Hutson; S M Fleming; N A Tetreaut; J Salcedo; E Masliah; M F Chesselet
Journal:  Synapse       Date:  2007-12       Impact factor: 2.562

Review 9.  Exploring the accessible conformations of N-terminal acetylated α-synuclein.

Authors:  Gina M Moriarty; Maria K Janowska; Lijuan Kang; Jean Baum
Journal:  FEBS Lett       Date:  2013-03-13       Impact factor: 4.124

Review 10.  Parkinson's disease.

Authors:  Timothy R Mhyre; James T Boyd; Robert W Hamill; Kathleen A Maguire-Zeiss
Journal:  Subcell Biochem       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.